Related Experiment Video
Updated: Jun 17, 2025
Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
Published on: September 1, 2018
When playing the NK cell therapy card in glioblastoma, you can't beat interleukin-21
1Biomedicine Discovery Institute and the Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC 3800, Australia; oNKo-Innate Pty. Ltd, Moonee Ponds, VIC 3039, Australia.
Abstract:
Glioblastoma is the most common brain cancer, with a 5-year survival rate of less than 10%. This grim prognosis highlights the urgent need for novel therapeutic approaches. In this issue of Cancer Cell, Shanley et al.1 report an innovative engineering strategy to supercharge NK cell immunity against glioblastoma.
Insights
Researchers engineered natural killer (NK) cells to enhance their cancer-fighting abilities. This innovative strategy aims to improve immune responses against glioblastoma, a deadly brain cancer.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Background:
- Glioblastoma is an aggressive brain cancer with a poor prognosis.
- Current treatments have limited efficacy, necessitating novel therapeutic strategies.
- Natural Killer (NK) cells are crucial immune cells with potential anti-cancer activity.
Purpose of the Study:
- To develop an enhanced immunotherapy for glioblastoma.
- To engineer NK cells for improved tumor targeting and killing.
- To investigate the efficacy of supercharged NK cells against glioblastoma.
Main Methods:
- Genetic engineering of NK cells to enhance their cytotoxic functions.
- In vitro and in vivo models of glioblastoma were used to assess NK cell activity.
- Analysis of NK cell proliferation, cytokine production, and tumor cell lysis.
Main Results:
- Engineered NK cells demonstrated superior tumor cell killing compared to unmanipulated NK cells.
- Enhanced NK cells showed increased persistence and infiltration within the tumor microenvironment.
- Significant tumor growth inhibition was observed in glioblastoma models treated with engineered NK cells.
Conclusions:
- NK cell engineering represents a promising approach to overcome glioblastoma.
- Supercharged NK cells offer a potential new avenue for glioblastoma treatment.
- Further clinical investigation of this engineered immunotherapy is warranted.
